These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34804001)

  • 1. Anti-PD-1 Therapy-A Potential Treatment for Myocardial Metastasis From Nasopharyngeal Carcinoma: A Case Report.
    Tang X; Zhou W; Huang D; Chen L; Zhang G
    Front Immunol; 2021; 12():688682. PubMed ID: 34804001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiotherapy Combined with PD-1 Inhibition Increases NK Cell Cytotoxicity towards Nasopharyngeal Carcinoma Cells.
    Makowska A; Lelabi N; Nothbaum C; Shen L; Busson P; Tran TTB; Eble M; Kontny U
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma.
    Ma Y; Chen X; Wang A; Zhao H; Lin Q; Bao H; Zhang Y; Hong S; Tang W; Huang Y; Yang Y; Wu X; Shao Y; Fang W; Zhang L
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.
    Finazzi T; Rordorf T; Ikenberg K; Huber GF; Guckenberger M; Garcia Schueler HI
    BMC Cancer; 2018 Apr; 18(1):395. PubMed ID: 29625593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
    Ahmed MM; Gebriel MG; Morad EA; Saber IM; Elwan A; Salah M; Fakhr AE; Shalaby AM; Alabiad MA
    Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):401-408. PubMed ID: 33480605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial data of Anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review.
    Adkins DR; Haddad RI
    Cancer Treat Rev; 2022 Sep; 109():102428. PubMed ID: 35753157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the PD-1/ PD-L1 interaction in nasopharyngeal carcinoma.
    Johnson D; Ma BBY
    Oral Oncol; 2021 Feb; 113():105127. PubMed ID: 33454551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case report: Leptomeningeal metastasis of advanced nasopharyngeal carcinoma treated with chemoimmunotherapy.
    Shi M; Sun D; Ma X; Liu J; Zhang Y; Liu T; Chen X; Mo S; Zhao Y; Zhang L
    Hum Vaccin Immunother; 2023 Dec; 19(3):2294579. PubMed ID: 38111107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 Induces Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma Cells Through Activation of the PI3K/AKT Pathway.
    Fei Z; Deng Z; Zhou L; Li K; Xia X; Xie R
    Oncol Res; 2019 Jul; 27(7):801-807. PubMed ID: 30982497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
    Wang FH; Wei XL; Feng J; Li Q; Xu N; Hu XC; Liao W; Jiang Y; Lin XY; Zhang QY; Yuan XL; Huang HX; Chen Y; Dai GH; Shi JH; Shen L; Yang SJ; Shu YQ; Liu YP; Wang W; Wu H; Feng H; Yao S; Xu RH
    J Clin Oncol; 2021 Mar; 39(7):704-712. PubMed ID: 33492986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Good prognostic factor in patients with nonmetastatic nasopharyngeal carcinoma: Programmed death ligand-1 expression in tumor cells.
    Sahinli H; Akyürek N; Yılmaz M; Kandemir O; Duran AO; Kulaçoǧlu S; Uçar G; Acar E; Özet A; Öksüzoǧlu OBÇ; Özdemir NY
    J Cancer Res Ther; 2020 Dec; 16(Supplement):S43-S47. PubMed ID: 33380650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma.
    Jiang F; Yu W; Zeng F; Cheng G; Xu J; Yang S; Shui Y; Wu D; Yu XF; Wei Q
    BMC Cancer; 2019 May; 19(1):503. PubMed ID: 31138162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?
    Masterson L; Howard J; Gonzalez-Cruz J; Jackson C; Barnett C; Overton L; Liu H; Ladwa R; Simpson F; McGrath M; Wallwork B; Jones T; Ottensmeier C; Chua MLK; Perry C; Khanna R; Panizza B; Porceddu S; Lechner M
    Int J Cancer; 2020 Apr; 146(8):2305-2314. PubMed ID: 31950498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prognostic Significance of APOBEC3B and PD-L1/PD-1 in Nasopharyngeal Carcinoma.
    Feng C; Zhang Y; Huang J; Zheng Q; Yang Y; Xu B
    Appl Immunohistochem Mol Morphol; 2021 Mar; 29(3):239-244. PubMed ID: 32205739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study).
    Yang Y; Zhou T; Chen X; Li J; Pan J; He X; Lin L; Shi YR; Feng W; Xiong J; Yang K; Yu Q; Zhang Q; Hu D; Sun Y; Hu G; Li P; Shen L; Lin Q; Zhang B; Qu X; Zou J; Zhang L; Fang W; Zhao Y
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34933967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective, single-arm trial of PD-1 inhibitors plus chemoradiotherapy for solitary metachronous metastasis nasopharyngeal carcinoma.
    Li L; Chen L; Fan M; Tian Y; Ai H; Yan L; Li F; Lan M; Lai X; Huang Y; Xu P; Feng M; Lang J
    Oral Oncol; 2024 Mar; 150():106695. PubMed ID: 38262250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution pattern and prognosis of metastatic lymph nodes in cervical posterior to level V in nasopharyngeal carcinoma patients.
    Jiang C; Gao H; Zhang L; Li H; Zhang T; Ma J; Liu B
    BMC Cancer; 2020 Jul; 20(1):667. PubMed ID: 32680466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma.
    Zhang J; Fang W; Qin T; Yang Y; Hong S; Liang W; Ma Y; Zhao H; Huang Y; Xue C; Huang P; Hu Z; Zhao Y; Zhang L
    Med Oncol; 2015 Mar; 32(3):86. PubMed ID: 25702326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis.
    Botticelli A; Cirillo A; Strigari L; Valentini F; Cerbelli B; Scagnoli S; Cerbelli E; Zizzari IG; Rocca CD; D'Amati G; Polimeni A; Nuti M; Merlano MC; Mezi S; Marchetti P
    Front Immunol; 2021; 12():705096. PubMed ID: 34434192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer.
    Chan OS; Kowanetz M; Ng WT; Koeppen H; Chan LK; Yeung RM; Wu H; Amler L; Mancao C
    Oral Oncol; 2017 Apr; 67():52-60. PubMed ID: 28351581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.